Hence, targeting HIF1α and HIF2α in tumors would not only suppress the “tumor promoting” actions of these transcription factors but by elevating SPRY2 gene transcription, elevate Spry2 protein levels and, therefore, the tumor suppressing actions of Spry2. Here, SPRY2 is linked to neoplasm.